Recombinant human activated protein C in the treatment of acute respiratory distress syndrome by Cornet, A.D. (Alexander) et al.
Recombinant Human Activated Protein C in the
Treatment of Acute Respiratory Distress Syndrome: A
Randomized Clinical Trial
Alexander D. Cornet1,2,3*, A. B. Johan Groeneveld1,3,4, Jorrit J. Hofstra5,6, Alexander P. Vlaar5,6,7,
Pieter R. Tuinman5,6, Arthur van Lingen8, Marcel Levi7, Armand R. J. Girbes1,3, Marcus J. Schultz5,6,
Albertus Beishuizen1,3,9
1Department of Intensive Care, VU University Medical Center, Amsterdam, The Netherlands, 2Department of Internal Medicine, VU University Medical Center,
Amsterdam, The Netherlands, 3 Institute for Cardiovascular Research ICaR-VU, VU University Medical Center, Amsterdam, The Netherlands, 4Department of Intensive
Care, Erasmus Medical Center, Rotterdam, The Netherlands, 5Department of Intensive Care, Academic Medical Center, Amsterdam, The Netherlands, 6 Laboratory of
Experimental Intensive Care and Anesthesiology, Academic Medical Center, Amsterdam, The Netherlands, 7Department of Internal Medicine, Academic Medical Center,
Amsterdam, The Netherlands, 8Department of Nuclear Medicine, VU University Medical Center, Amsterdam, The Netherlands, 9Department of Intensive Care, Medisch
Spectrum Twente, Enschede, The Netherlands
Abstract
Rationale: Pulmonary coagulopathy may play a pathogenetic role in acute respiratory distress syndrome (ARDS), by
contributing to alveolocapillary inflammation and increased permeability. Recombinant human activated protein C (rh-APC)
may inhibit this process and thereby improve patient outcome.
Methods: A prospective randomized, saline-controlled, single-blinded clinical trial was performed in the intensive care units
of two university hospitals, and patients with ARDS were included within 24 h after meeting inclusion criteria.
Intervention: A 4-day course of intravenous rh-APC (24 mcg/kg/h) (n = 33) versus saline (n = 38).
Outcomes: The primary outcome parameter was the pulmonary leak index (PLI) of 67Gallium-transferrin as a measure of
alveolocapillary permeability and secondary outcomes were disease severity scores and ventilator-free days, among others.
Results: Baseline characteristics were similar; in 87% of patients the PLI was above normal and in 90% mechanical or non-
invasive ventilation was instituted at a median lung injury score of 2.5. There was no evidence that Rh-APC treatment
affected the PLI or attenuated lung injury and sequential organ failure assessment scores. Mean ventilator-free days
amounted to 14 (rh-APC) and 12 days (saline, P = 0.35). 28-day mortality was 6% in rh-APC- and 18% in saline-treated
patients (P = 0.12). There was no difference in bleeding events. The study was prematurely discontinued because rh-APC
was withdrawn from the market.
Conclusion: There is no evidence that treatment with intravenous rh-APC during 4 days for infectious or inflammatory ARDS
ameliorates increased alveolocapillary permeability or the clinical course of ARDS patients. We cannot exclude
underpowering.
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Introduction
Acute respiratory distress syndrome (ARDS), with its milder
form formerly known as acute lung injury (ALI), occurs in 30 to 80
per 100,000 person-years and is a major cause of morbidity and
mortality in the critically ill [1,2]. Treatment of ARDS is
supportive since there are no routine drugs for treatment, other
than treatment of the underlying disease [3]. A key factor in the
pathogenesis of ARDS is alveolocapillary inflammation, leading to
endothelial barrier dysfunction and increased permeability, that
can be assessed at the bedside, with help of the non-invasively
measured pulmonary leak index (PLI) of 67Gallium (67Ga)-
transferrin [4–6]. In previous studies it was demonstrated that
the PLI parallels the clinical severity and course of ARDS, for
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instance expressed as changes in the lung injury score [5].
Furthermore, the PLI appeared to be more accurate in assessing
the degree of permeability than extravascular lung water
measurements [7].
There is an extensive crosstalk between inflammation, activated
coagulation and depressed fibrinolysis, so that alveolar fibrin
depositions and small vessel thrombi are thought to contribute and
perpetuate alveolocapillary inflammation, pulmonary vascular
injury and barrier dysfunction [3,8–11]. The alveolar and systemic
levels of naturally occurring anticoagulants, such as activated
protein C (APC), may be depressed because of consumption,
impaired synthesis and degradation, and inhibitors of fibrinolysis
may be increased, and both phenomena may be associated with
pulmonary and remote organ dysfunction and mortality [8,9]. In
healthy volunteers, infusion of rh–APC attenuated coagulopathy
and neutrophils in the lungs after inhalation of endotoxin [12,13].
This is in line with beneficial effects of rh–APC infusion in models
of sepsis and ARDS on pulmonary coagulopathy and consequently
on alveolocapillary inflammation, as well as with directly
ameliorating effects on endothelial barrier dysfunction via
stimulation of protease-activated receptor-1 (PAR-1), protein C
and sphingosine-1-phosphate (S1P) receptors in the endothelium
[11,14,15]. The latter may downregulate, among others, pulmo-
nary endothelial release of angiopoietin-2 that may play a direct
role in the increased permeability in patients with ARDS, and may
attenuate cytoskeletal rearrangement via Rho-associated kinase
[11,14–17]. In patients with severe sepsis, often accompanied by
ARDS, infusion of recombinant human (rh) APC reduced
mortality by ameliorating organ dysfunction, including respiratory
dysfunction as demonstrated in two multicenter trials (PROWESS,
ENHANCE) [18,19,20]. Of note, infusion was particularly
effective in patients who presented with lung infection, commu-
nity–acquired pneumonia or need for mechanical ventilation
[21,22]. In a recent large study in patients with septic shock
(PROWESS SHOCK), rh-APC appeared of no benefit and was
withdrawn from the market after publication, although two prior
multicenter trials (ADDRESS, RESOLVE) already raised con-
cerns regarding its efficacy [23–25]. About 43% had a pulmonary
origin of sepsis in the PROWESS-SHOCK trial. In a recent meta-
analysis, including the aforementioned negative trial [25],
however, the drug was suggested to maintain effectiveness [26].
For the current study, performed before publication of the last
multicenter study on APC [25], we hypothesized that infusion of
rh–APC attenuates the increase in pulmonary vascular perme-
ability and thereby benefits patients with ARDS as a single organ
failure. We performed a single-blinded, randomized controlled
multicenter trial of patients with ARDS comparing intravenous
infusion of rh–APC with saline, studying the effect on the PLI as
primary outcome measure [4–6]. Secondary outcomes included
lung injury score (LIS) and sequential organ failures score (SOFA),
duration on mechanical ventilation and ventilator-free days, and
mortality. A substudy of our trial was recently published and
suggested attenuated hypercoagulability, increased fibrinolysis and
thereby less lung injury by rh-APC treatment [27].
Patients and Methods
Study design
This is a report of the infectious and inflammatory ALI/ARDS
(INFALI) trial, a multicenter prospective, single-blinded, random-
ized, saline-controlled clinical trial in patients with ALI/ARDS
(trial registration number ISRCTN 52566874). The patients were
blinded for the allocated treatment. The Ethics Committee of the
VU University Medical Center, Amsterdam, the Netherlands,
approved the study protocol. Written informed consent was
obtained from all patients or their next of kin before enrolment in
the trial. All clinical investigations have been conducted according
to the principles expressed in the Declaration of Helsinki. The
protocol for this trial and supporting CONSORT checklist are
available as supporting information; see Checklist S1 and Protocol
S1.
Inclusion and exclusion criteria
Patients, over 18 years of age and admitted to the mixed
medical–surgical intensive care units (ICU’s) of two participating
university medical centers in Amsterdam, were to be included
because of respiratory insufficiency within 24 hours after diagnosis
of ALI/ARDS, of any cause, including pneumonia, sepsis,
aspiration according to standard clinical criteria, irrespective of
the need for ventilatory support. The definition used to establish
the diagnosis pneumonia was radiographic evidence of pulmonary
consolidation in association with the production of purulent
sputum with plus two positive SIRS criteria (1. core temperature of
Figure 1. CONSORT diagram. ARDS, acute respiratory distress syndrome; SCT, stem cell transplantation; plts, platelet count.
doi:10.1371/journal.pone.0090983.g001
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Table 1. Baseline characteristics.
rh-APC (n=33) saline (n =38) P-value
Age 62.2614.4 60.6617.7 0.940
Sex (male) 15 (45) 25 (66) 0.099
Height (cm) 168.568.7 172.869.6 0.097
Weight (kg) 73.9614.9 71.6616.3 0.518
Comorbidities
Cardiovascular 15 (45) 21 (55) 0.479
Pulmonary 5 (15) 14 (37) 0.059
Renal 1 (3) 3 (8) 0.618
malignancy 4 (12) 6 (16) 0.739
Etiology of ARDS
pneumonia 27 (82) 34 (89) 0.242
abdominal sepsis 3 (9) 1 (3)
near-drowning 0 2 (5)
smoke inhalation 2 (6) 0
miscellaneous 1 (3) 1 (3)
Severity of ARDS (Berlin criteria)
mild 9 (27) 12 (32) 0.582
moderate 23 (70) 23 (61)
severe 1 (3) 3 (7)
Blood stream infection 6 10 0.459
Streptococcus pneumoniae 3 4
Listeria monocytogenes 1 0
Enterococcus faecium 0 1
Coagulase-negative staphylococcus 2 5
Tracheal aspirate
Streptococcus pneumoniae 3 8 0.685
Beta-haemolytical streptococcus 1 -
Staphylococcus aureus 2 6
Enterococcus faecalis 1 -
Listeria monocytogenes 1 -
Escherichia coli 3 4
Pseudomonas aeruginosa 4 1
Proteus mirabilis - 2
Hafnia alveii 2 -
Enterobacter cloacae 1 -
Haemophilus influenzae 1 2
Klebsiella oxytoca 1 -
Klebsiella pneumoniae - 3
Aeromonas spp - 1
Pneumocystis jirovecii 1 -
Aspergillus spp 2 1
Candida spp 2 3
Disease severity
APACHE II 17.366.2 16.965.4 0.707
SAPS II 41.5612.8 37.8612.8 0.266
SOFA 7.362.3 7.062.0 0.867
Vital signs
Temperature (uC) 36.661.4 36.561.7 0.703
Heart rate (/min) 101.0632.2 112.3627.8 0.121
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$38uC or #36uC; 2. heart rate of $90 beats/min; 3. respiratory
rate $20 breaths/min or a PaCO2 #32 mmHg or the use of
mechanical ventilation for an acute respiratory process; 4. white
cell count $12,000/mm3 or #4,000/mm3 or a differential count
showing .10% immature neutrophils) [28]. This was adjudicated
by ADC, JJH, MJS and AB. ALI/ARDS was diagnosed using the
North American European Consensus Conference (NAECC)
definition [29]. Although inclusion was on the basis of ALI/
ARDS, we recoded conditions according to the current Berlin
definition of ARDS, according to variables at enrollment [2].
Table 1. Cont.
rh-APC (n=33) saline (n =38) P-value
MAP (mmHg) 69.9611.7 69.0616.2 0.503
Treatment
Vasopressors 26 (79) 30 (79) 1.000
Corticosteroids 23 (70) 24 (63) 0.800
Duration between admission and start of study (days) 1.863.4 1.762.4 0.595
Mean/median 6 standard deviation/interquartile range, respectively, or number (percentage), where appropriate. Rh-APC, recombinant human activated protein C;
APACHE, acute physiology and chronic health evaluation; SAPS, simplified acute physiology score; SOFA, sequential organ failure assessment; MAP, mean arterial
pressure.
doi:10.1371/journal.pone.0090983.t001
Table 2. Pulmonary variables.
Baseline) Day 5 Day 15
rh-APC saline P rh-APC saline P rh-APC saline P
(n =33) (n =38) (n=33) (n =38) (n =19) (n =11)
Gasometrics
PaO2, mmHg 88.0621.5 88.9623.0 0.921 88.8619.2 90.7627.7 0.756 89.7617.8 84.867.7 0.713
FIO2, % 53.1612.5 55.2616.8 0.924 43.969.9 44.3611.2 0.965 41.4610.8 40.866.7 0.868
PaO2/FIO2 175.1648.6 170.7653.8 0.624 220.2672 217.7695.4 0.732 227.7669.8 213.8641.3 0.483
PaCO2, mmHg 45.7612.5 47.2611.6 0.604 43.369.7 45.669.3 0.393 45.2611.91 44.465.3 0.867
pH 7.3660.08 7.3460.10 0.390 7.4460.05 7.4260.07 0.502 7.4360.04 7.4460.02 0.524
Ventilation
Mode 0.551 0.551 0.702
Unassisted breathing 4 (12) 3 (8) 4 (12) 3 (8) 7 (37) 3 (27)
Invasive ventilation 29 (88) 34 (89) 29 (88) 34 (89) 12 (63) 8 (73)
Non-invasive
ventilation
0 1 (3) 0 1 (3) 0 0
Prone position 5 (15) 11 (29) 0.255 5 (15) 11 (29) 0.255 1 (5) 0 1.000
Respiratory rate (/min) 25.866.3 25.566.1 0.766 20.864.9 22.664.8 0.288 23.864.8 23.464.1 0.928
PIP (cm H2O) 32.069.3 31.667.5 0.989 26.068.8 26.268.4 0.825 23.3610.5 18.466.1 0.384
PEEP (cm H2O) 12.364.6 12.864.3 0.819 11.064.3 10.764.2 0.839 9.863.8 8.562.8 0.482
Tidal volume (mL) 459696 4516120 0.544 449676 476677 0.193 430665 407674 0.571
Tidal volume (mL/kg
IBW)
7.561.8 6.862.0 0.091 7.461.4 7.361.9 0.628 7.461.1 6.361.9 0.135
Compliance (mL/cm
H2O)
24.567.8 24.366.5 0.843 33.5613.4 32.9611.7 0.944 40.8623.1 50.8629.6 0.343
Chest radiograph
quadrants
2.260.9 1.960.7 0.249 1.760.8 1.660.8 0.851 1.061.1 1.561.2 0.245
Lung injury
PLI (x10-3/min) 33.8620.7 31.2620.6 0.335
Lung injury score 2.560.7 2.560.6 0.862
Mean or median 6 standard deviation or interquartile range, respectively, or number (percentage), where appropriate. Rh-APC, recombinant human activated protein
C; PaO2, partial pressure of O2; FIO2, inspiratory O2 fraction; PIP, peak inspiratory pressure; PEEP, positive end-expiratory pressure; IBW, ideal body weight; PLI, pulmonary
leak index; LIS, lung injury score (between 0 and 4).
doi:10.1371/journal.pone.0090983.t002
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Patients were excluded if rh–APC treatment was indicated based
on national guidelines at the time of the study (i.e., severe sepsis or
septic shock, acute physiology, age and chronic health evaluation
II score (APACHE II) score $25 and in the absence of informed
consent [30]. Additional exclusion criteria were: platelet count
,306109/L, any major surgery within 12 hours before inclusion,
acute bleeding, severe head trauma, intracranial surgery or stroke
within 3 months before inclusion, known intracranial abnormal-
ities (e.g., malignancies or other tumors, arteriovenous malforma-
tion), known hypercoagulability (e.g., protein C resistance,
hereditary deficiency of protein C, protein S or antithrombin, or
anticardiolipin– or antiphospholipid–antibodies), congenital hem-
orrhagic diathesis, pregnancy or breast feeding, liver cirrhosis with
portal hypertension and/or esophageal varices, presence of an
epidural catheter; severely immune–compromised status (e.g.,
HIV–infected patients with CD4 count ,50/mL, and patients
treated with immunosuppressive medication following bone
marrow or solid organ transplantation). The following concomi-
tant medications were reasons for exclusion: heparin in therapeu-
tic dose (within 8 hours of study entry), coumarin derivatives at
any dose (within 7 days of study entry), acetylsalicylic acid at a
dose .650 mg/day (within previous 3 days of study entry),
thrombolytic therapy at any dose (within previous 3 days of study
entry), glycoprotein IIb/IIIa inhibitors at any dose (within 7 days
of study entry), antithrombin at any dose (within 3 days of study
entry) and previous treatment with rh–APC (at any time within
study entry). Prophylactic dose of low molecular weight heparin
was allowed.
Treatment protocol
All patients were treated by the discretion of the supervising
intensivists according to international guidelines. If needed,
mechanical ventilation was performed after endotracheal intuba-
tion, in a pressure–controlled mode, aiming at a maximum airway
pressures ,35 cmH2O, and tidal volumes #6 mL/kg predicted
ideal body weight (Devine formula), with or without proning,
when indicated on clinical grounds. Patients receiving mechanical
ventilation after endotracheal intubation underwent selective
decontamination of the digestive tract after collection of tracheal
aspirate cultures, oropharyngeal and perineal swabs. Antibiotic
therapy was guided by Gram–stains and cultures, according to
local guidelines for antimicrobial therapy. Fluid therapy consisted
of crystalloids, with or without gelatins and/or hydroxyethyl
starches, in order to maintain arterial blood pressure (MAP
.70 mmHg) and diuresis (.30 mL/h).
Study protocol
Patients were randomly assigned to infusion of rh–APC or a
similar volume of normal saline. Prior to the start of the trial sealed
opaque envelopes, containing the treatment assignment for each
patient, were numbered through block randomization, with 6
blocks of patients, stratified per participating unit. Open label rh–
APC (Eli Lilly, Indianapolis, IN, USA), at a dose of 24 mcg/kg/h,
or saline was infused at a constant rate for a total of 96 hours,
starting within 6 hours after randomization. Randomization was
within 12 h after meeting above inclusion criteria. Infusion of rh–
APC was interrupted 1 hour before any invasive percutaneous
procedure or major surgery. When no bleeding complications
occurred, infusion of rh–APC was resumed 1 hour after a
percutaneous procedure, and 12 hours after major surgery, in
line with international guidelines. All patients completed the 96-
hour treatment. No patient met the criteria for APC administra-
tion according to the national guidelines prevailing at the time of
the study.
PLI
The PLI was measured within 0–4 hours prior to the start of
infusion of the study drug or saline, and repeated within 12 hours
following the end of 96 hour infusion, according to published
methods [4–6]. Transferrin was labeled in vivo, after intravenous
injection of 4–5 MBq 67Ga-citrate (physical half-life 78 hrs;
Mallinckrodt Diagnostica, Petten, the Netherlands). Patients were
in supine or prone position, and two scintillation probes (Eurorad
C.T.T., Strasbourg, France) were placed over the left and right
lung apices. Starting from the time of 67Ga injection, radioactivity
was measured for 30 minutes. The 67Ga counts are corrected for
background activity, physical half-life of 67Ga and decay after
injection, and expressed as counts per minute per lung. At 0, 5, 8,
12, 15, 20, 25 and 30 minutes, blood samples were taken. Each
blood sample was weighed and radioactivity was measured with a
single-well well-counter (LKB Wallac 1480 WIZARD, Perkin
Elmer, Life Science, Zaventem, Belgium) taking background and
physical half-life into account. Results are expressed as counts per
minute per gram. For each blood sample, a time-matched counts
per minute over each lung was taken. The radioactivity ratio was
calculated as (67Galung)/(
67Gablood) and plotted against time. The
PLI was calculated from the slope of the increase of the
radioactivity ratio, divided by the intercept, to correct for physical
factors in radioactivity detection and pulmonary blood volume.
The PLI thus represents the transport rate of 67Ga-transferrin
from the intravascular to the extravascular space of the lungs and
is therefore a measure of pulmonary vascular permeability. The
values for both lungs were averaged. The upper limit of normal for
the PLI is 14.161023/min, and the measurement error (coeffe-
cient of variation if measurement is repeated in the same patient) is
approximately 10% [31].
Data collection
Upon enrolment, data on baseline demographics, comorbidity
and reasons of admission to the intensive care unit (ICU), as well
Table 3. Primary and secondary outcome measures.
rh-APC
(n=33)
saline
(n =38) P-value
Primary outcome
PLI day 5,61023/min 26.2616.0 27.0615.8 0.878
Decrease PLI day 1–5,61023/min 9.1624.2 4.6618.1 0.619
Secondary outcomes
LIS day 5 1.860.9 1.961.0 0.654
LIS day 15 1.561.1 1.861.0 0.327
Ventilator-free days (days) 14.5610.5 12.0611.3 0.348
Duration of ventilation (days) 12.469.9 12.2610.0 0.958
SOFA day 5 5.463.2 5.263.5 0.744
SOFA day 15 4.562.5 3.862.5 0.396
28-day mortality 2 (6) 7 (18) 0.157
ICU mortality 5 (15) 11 (29) 0.255
90-day mortality 6 (18) 11 (29) 0.404
Hospital mortality 7 (21) 12 (32) 0.423
Mean or median 6 standard deviation or interquartile range, respectively, or
number (percentage), where appropriate. Rh-APC, recombinant human
activated protein C; PLI, pulmonary leak index; LIS, lung injury score; SOFA,
sequential organ failure assessment; ICU, intensive care unit.
doi:10.1371/journal.pone.0090983.t003
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as hemodynamic and respiratory parameters were collected. The
APACHE II [30], the simplified acute physiology score (SAPS
II)[32], the sequential organ failure assessment score (SOFA) [33]
and the lung injury score (LIS) [34] were calculated from worst
values in the 24 h preceding enrolment and, for SOFA and LIS,
on day 5 and 15 after enrolment. For the LIS we evaluated daily
chest radiographs and scored the number of consolidated
quadrants. From the blood gas measurements, done for routine
care, daily worst values were taken and also the worst ventilatory
settings were taken from the patient data management system
available in the units. Total respiratory dynamic compliance was
calculated from tidal volume/(peak inspiratory pressure - positive
end expiratory pressure), mL/cm H2O. We estimated in patients
not on mechanical ventilation the inspiratory O2 fraction (FIO2)
from liters of O2 administered nasally or via non-rebreathing
mask, varying between 1 and 15 L, yielding an estimated FIO2
from 23 to 70%, respectively. The number of ventilator-free days
(VFD) was defined as the number of days with unassisted
breathing (.24 h) from randomization to day 28 after enrolment.
Patients who died before day 28 while receiving ventilator support,
were assigned zero ventilator-free days [35]. Lengths of stay and
mortality at day 28 and 90 were recorded, within or outside the
ICU or the hospital.
Statistical analysis
The study was powered (at 80%) to include 96 patients to detect
an anticipated difference in PLI of 20% at a standard deviation
(SD) of 40% (a=0.05). The Kolmogorov-Smirnov test was used to
check for normal data distribution (if P.0.05). Data were
expressed as means (6 standard deviation) for normally distributed
data, medians (6 interquartile range) for non-normally distributed
data, or absolute numbers where appropriate. Nonparametric data
were analyzed using Mann–Whitney U and categorical data by
Fisher’s exact test. The Spearman rank correlation was used to
express relations. Kaplan-Meier plots were made and a log rank
test performed for ventilatory independency and survival in time in
the groups. A Cox proportional-hazards model was used to
estimate the hazard ratio (HR) for death with the use of rh-APC
versus saline in different posthoc defined subgroups (with 95%
confidence intervals). A P value of ,0.05 was considered
statistically significant and exact values are given unless ,0.001.
Statistical analysis was performed using SPSS 19.0 (SPSS,
Figure 2. Probability of being alive and off the ventilator until day 28 in study groups.
doi:10.1371/journal.pone.0090983.g002
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Chicago, IL, USA) and Prism 5.0 (GraphPad Software, San
Diego, CA, USA).
Results
Between 1 January 2007 and 1 May 2011 9,484 patients were
assessed for eligibility (Fig. 1). Of these patients, 71 patients were
enrolled in the study. Reasons for exclusion are given in Fig. 1.
There were 33 patients assigned to rh-APC and 38 to saline. The
study was prematurely discontinued because rh-APC was with-
drawn form the market and no longer commercially available.
Baseline characteristics
Patient groups did not differ with regard to demographic and
baseline parameters (Table 1). In 61 patients the reason for
inclusion was pneumonia. There was a trend towards more
pulmonary comorbidity in the saline-treated group. With regard to
disease severity as expressed by APACHE II and SAPS II scores,
groups did not differ. Furthermore, the frequency of treatment
with vasopressors and steroids was similar. In the majority of
patients (56/71) tracheal aspirate cultures were positive. In 14
patients (n = 5 rh-APC and n= 9 saline) multiple pathogens were
isolated. Streptococcus pneumoniae was the most prevalent identified
micro-organism, both in tracheal aspirate and in blood cultures.
Ninety percent of the patients (64/71) needed invasive mechanical
ventilation.
Pulmonary variables
At baseline, the PLI was increased as compared to normal
values in 87% (62/71) of patients. The baseline PLI and LIS,
which did not differ among groups, correlated at Rs = 0.26,
P= 0.030 (Table 2). The baseline LIS was associated with the
duration of mechanical ventilation (Rs = 0.33, P= 0.005). There
were no differences between groups in the course of ventilator
pressures, tidal volumes, gas exchange, and oxygen requirements.
Primary and secondary outcome measures
Table 3 shows that there is no difference in day 5 PLI between
treatment groups, although the reduction in PLI was more
pronounced in the rh-APC group, yet not reaching statistical
significance. There was no effect of rh-APC on the general disease
severity score (SOFA) nor the more lung-specific LIS and the
number of ventilator-free days. Fig. 2 shows the lack of difference
in ventilator-dependency in the groups until day 28 after
Figure 3. Probability of survival until day 28 in study groups.
doi:10.1371/journal.pone.0090983.g003
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randomization. The day 5 LIS score was associated with the
duration of mechanical ventilation (Rs = 0.58, P,0.001). With
regard to mortality, no differences were found between treatment
groups (Table 3 and Fig. 3 & 4).
Post-hoc subgroup analysis
Cox regression analysis did not identify any subgroup in which
treatment with rh-APC resulted in a statistically significant survival
benefit, even though all HR were below 1 (Table 4). In patients
with pneumonia and supranormal PLI the P for 28-day survival
with log-rank testing was 0.045 in favor of rh-APC.
Adverse events
Two pneumothoraces occurred during the study, one in each
patient group. There were no bleeding complications.
Discussion
Our study suggests that a 4-day course of intravenous rh-APC
does not ameliorate the increased permeability and clinical course
of ARDS in critically ill patients. However, our study was
underpowered.
The study was designed with the hypothesis that APC plays a
role in the endothelial barrier function in the lung. The study was
powered for a 20% change in PLI since increased alveolocapillary
permeability was considered central in the pathogenesis and
clinical presentation of ARDS [4–6]. We previously demonstrated
that the PLI increases before ARDS becomes clinically manifest
and declines when it resolves [4]. Our current study again
documents that increased permeability is associated with the
clinical manifestations of ARDS expressed as the LIS, as noted
before [4–6], and that the latter is a determinant of duration of
ventilatory support. Yet, in a substudy of this trial, we
demonstrated that rh-APC infusion actually attenuates pulmonary
coagulopathy [27]. Apparently, this effect on pulmonary coagu-
lopathy does not result in a clinically significant enhancement of
barrier function as expressed by the PLI. Therefore, we could not
find evidence for the concept that rh-APC ameliorates endothelial
barrier dysfunction and increased permeability and thereby
attenuates the course of ARDS in man, as suggested by preclinical
studies via a cytoprotective effect involving PAR-1 and S1P
pathways, irrespective of anti-inflammatory effects [11,14,15]. In
some animal studies (rats with pulmonary infection) intravenous
Figure 4. Probability of survival until day 90 in study groups.
doi:10.1371/journal.pone.0090983.g004
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administration of rh-APC limited bronchoalveolar coagulation,
whereas it did not exert anti-inflammatory effects [36,37].
The 28-day mortality rate of patients in our study was relatively
low (13%), likely attributable to a lower overall disease severity, as
severe sepsis, septic shock and APACHE II $25 were exclusion
criteria, when compared with large international trials on ARDS
that did not exclude the latter patients and reported mortality rates
of 25 to 46% [38,39]. It was however comparable to the 60-day
mortality rate of 13% in the trial of Liu et al., who applied similar
inclusion criteria for the 75 patients in their study, of whom only
40% had pneumonia [35]. Additionally, our study is in line with
the results from the ADDRESS (Administration of Drotrecogin
Alfa (Activated) in Early Stage Severe Sepsis) trial, focusing on
patients with relatively low disease severity (APACHE II ,25 or
single organ failure) suffering from severe sepsis in whom rh-APC
administration did not show clinical benefits [23]. In the double-
blind, phase III, RESOLVE (REsearching severe Sepsis and
Organ dysfunction in children; a gLobal perspectiVE) trial, 477
children with severe sepsis were enrolled. Again, there was no
difference between rh-APC and placebo with regard to the
composite time to complete organ failure resolution score.
Mortality at 28 days was 17.2% in the rh-APC group versus
17.5% in the placebo group [24].
The limitations of our study include its premature discontinu-
ation because rh-APC was withdrawn from the market, as
described before [25]. The stringent exclusion criteria that we
applied in order to reduce bleeding risks, contributed to the small
number of patients that were enrolled. As a result, our study is
underpowered to demonstrate amelioration of increased perme-
ability and clinical course of ARDS in critically ill patients by
intravenous rh-APC, as well as to demonstrate an effect on
mortality, particularly in pneumonia-induced ARDS with in-
creased alveolocapillary permeability. The single prior study on
human ALI (n= 75), which also proved negative [35], was
underpowered as well. Their case mix was more heterogeneous
than in our study (only 40% had pneumonia) [35], suggesting that,
when even in a more homogeneous population a benefit cannot be
demonstrated, the contributory role of APC in ARDS must indeed
be low. Nevertheless, our post hoc analyses, which should be
interpreted with caution, serve to suggest the validity of trial
design. The tidal volumes delivered to the patients in our study
were larger than the 6 mL/kg ideal body weight described in the
treatment protocol. However, the tidal volumes were comparable
in both treatment groups throughout the study period. Moreover,
the mean tidal volumes were within the range of 6 to 8 mL/kg
ideal body weight, which is in keeping with the suggested lung-
protective mechanical ventilation strategies in the Surviving Sepsis
Campaing Guidelines [40].
The external validity of our study is compromised, as it was
performed in 2 centers. The possibility of recruiting more centers
Table 4. Hazard ratios for death on day 28.
No. of No. of deaths (%) HR (95% CI)
patients rh-APC saline
All patients 71 2 (6) 7 (18) 0.310 (0.064–1.492)
Etiology of ARDS
pneumonia 61 1(4) 7 (20) 0.165 (0.020–1.342)
other 10 1 (17) 0 -
Berlin criteria for ARDS
mild 21 0 2 (17) -
moderate/severe 50 2 (8) 5 (19) 0.414 (0.080–2.136)
Pulmonary leak index
above normal 60 2 (7) 7 (22) 0.304 (0.063–1.462)
$26 upper limit of normal 32 1 (6) 4 (27) 0.208 (0.023–1.861)
,26 upper limit of normal 39 1 (7) 3 (13) 0.511 (0.053–4.917)
$2.56upper limit of normal 22 0 4 (36) -
,2.56upper limit of normal 49 2 (10) 3 (11) 0.865 (0.145–5.176)
Lung injury score
$2.5 39 2 (11) 4 (19) 0.577 (0.106–3.152)
,2.5 32 0 3 (18) -
Sequential organ failure assessment
$7 48 2 (9) 6 (24) 0.334 (0.067–1.658)
,7 23 0 1 (8) -
Baseline steroids
Yes 47 2 (9) 6 (25) 0.320 (0.064–1.583)
no 24 0 1 (7) -
C-reactive protein
$175 mg/L 32 1 (63) 4 (25) 0.233 (0.026–2.089)
,175 mg/L 37 1 (7) 3 (14) 0.461 (0.048–4.429)
ARDS, acute respiratory distress syndrome; HR, hazard ratio with 95% confidence intervals.
doi:10.1371/journal.pone.0090983.t004
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was deemed impossible, both practically and logistically. The PLI
measurements require highly specialized, custom-made scintilla-
tion probes. Furthermore, since many hospitals do not have a
department of nuclear medicine, the isotopes would have needed
to be transported via public roads for which government
permission would have been needed, as well as additional
permission for transportation through the hospital and adminis-
tration in the ICU. Then the radioactive blood samples would
have been needed to be transported back to one of both academic
centers to perform the radioactivity count.
Our study is a single-blinded study. As a part of standard care,
APTT and PT are regularly monitored in both centers. As rh-APC
prolongs APTT, a truly double-blinded study was not considered
feasible.
Conclusion
In conclusion, this study suggests that treatment for 4 days with
intravenous rh-APC for infectious or inflammatory ARDS does
not ameliorate increased alveolocapillary permeability nor the
clinical course of critically ill patients with ARDS as a single organ
failure mostly caused by pneumonia.
Key messages
N Increased pulmonary vascular permeability is associated with
the clinical manifestations of ARDS
N Intravenous rh-APC for 4 days does not ameliorate increased
alveolocapillary permeability nor the clinical course of
critically ill patients with infectious or inflammatory ARDS
as a single organ failure
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